Document Detail


Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
MedLine Citation:
PMID:  11406737     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study the effects of rifampin (INN, rifampicin) on the pharmacokinetics and pharmacodynamics of glyburide (INN, glibenclamide) and glipizide, 2 sulfonylurea antidiabetic drugs. METHODS: Two separate, randomized, 2-phase, crossover studies with an identical design were conducted. In each study, 10 healthy volunteers received 600 mg rifampin or placebo once daily for 5 days. On day 6, a single dose of 1.75 mg glyburide (study I) or 2.5 mg glipizide (study II) was administered orally. Plasma glyburide and glipizide and blood glucose concentrations were measured for 12 hours. RESULTS: In study I, rifampin decreased the area under the plasma concentration--time curve [AUC(0-infinity)] of glyburide by 39% (P <.001) and the peak plasma concentration by 22% (P =.01). The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin. The blood glucose decremental AUC(0-7) (net area below baseline) and the maximum decrease in the blood glucose concentration were decreased by 44% (P =.05) and 36% (P <.001), respectively, by rifampin. In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01). No statistically significant differences in the blood glucose concentrations were found between the phases; however, 4 subjects had moderate hypoglycemia during the placebo phase but only 1 subject had moderate hypoglycemia during the rifampin phase. CONCLUSIONS: Rifampin moderately decreased the plasma concentrations and effects of glyburide but had only a slight effect on glipizide. The mechanism underlying the interaction between rifampin and glyburide is probably induction of either CYP2C9 or P-glycoprotein or both. Induction of CYP2C9 would explain the increased systemic elimination of glipizide. It is probable that the blood glucose--lowering effect of glyburide is reduced during concomitant treatment with rifampin. In some patients, the effects of glipizide may also be reduced by rifampin.
Authors:
M Niemi; J T Backman; M Neuvonen; P J Neuvonen; K T Kivistö
Related Documents :
18691987 - Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: ...
3729137 - Thiacetarsamide in dogs: disposition kinetics and correlations with selected indocyanin...
8070317 - Disposition kinetics of d- and l-amphetamine following intravenous administration of ra...
1768567 - Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers c...
21376717 - Effect of pf-04217329 a pro-drug of a selective prostaglandin ep(2) agonist on intraocu...
16152757 - A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (vx...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  69     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-14     Completed Date:  2001-07-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  400-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibiotics, Antitubercular / pharmacology*
Area Under Curve
Blood Glucose / metabolism
Female
Glipizide / blood,  pharmacokinetics*
Glyburide / blood,  pharmacokinetics*
Half-Life
Humans
Hypoglycemic Agents / blood,  pharmacokinetics*
Male
Rifampin / pharmacology*
Chemical
Reg. No./Substance:
0/Antibiotics, Antitubercular; 0/Blood Glucose; 0/Hypoglycemic Agents; 10238-21-8/Glyburide; 13292-46-1/Rifampin; 29094-61-9/Glipizide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anaphylactoid reactions to vitamin K.
Next Document:  Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patien...